Trial Profile
The Effect of a Progesterone Receptor Modulator on Breast Tissue in Women With BRCA-1 and -2 Mutations - a Placebo Controlled RCT
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 15 Jan 2022 Status changed from recruiting to completed.
- 16 Feb 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 16 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.